search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Delirium treatment at the geriatric ward (DELTa G) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward. A randomized placebo-controlled study.


- candidate number1847
- NTR NumberNTR533
- ISRCTNIncomplete data for ISRCTN
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-nov-2005
- Secondary IDsN/A 
- Public TitleDelirium treatment at the geriatric ward (DELTa G) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward. A randomized placebo-controlled study.
- Scientific TitleDelirium treatment at the geriatric ward (DELTa G) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward. A randomized placebo-controlled study.
- ACRONYMDELTa G
- hypothesisRivastigmine is as effective as haloperidol in the treatment of a delirium.
- Healt Condition(s) or Problem(s) studiedDelirium
- Inclusion criteriaPatients on a geriatric ward and delirium.
- Exclusion criteria1. Already use of rivastigmine/donepezil or galantamine;
2. Parkinson(ism).
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- group[default]
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2006
- planned closingdate1-jan-2009
- Target number of participants100
- Interventions1. Haloperidol;
2. Rivastigmine.
- Primary outcomeLength of delirium.
- Secondary outcome1. Length of stay in hospital;
2. Severity of delirium;
3. Need of escape medication;
4. Functional status, 3, 6 and 13 weeks after delirium;
5. Cognition.
- TimepointsN/A
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDr. P.L.J. Dautzenberg
- CONTACT for SCIENTIFIC QUERIESDr. P.L.J. Dautzenberg
- Sponsor/Initiator
- Funding
(Source(s) of Monetary or Material Support)
Novartis Pharma B.V.
- PublicationsN/A
- Brief summaryN/A
- Main changes (audit trail)
- RECORD23-nov-2005 - 17-apr-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl